Daily Medication Pearl: Ribociclib (Kisqali) for Breast Cancer

Ribociclib is an inhibitor of cyclin-dependent kinase 4 and 6 and causes tumor growth inhibition.

Medication Pearl of the Day: Ribociclib (Kisqali)

Ribociclib is a kinase inhibitor indicated for breast cancer.

Insight:

  • Ribociclib tablets are taken orally, with or without food, in combination with an aromatase inhibitor or Fulvestrant.
  • Recommended starting dose: 600 mg orally taken once daily, with or without food, for 21 consecutive days followed by 7 days off treatment.
  • Dosage comes in 200 mg tablet format.
  • Mechanism of action: Ribociclib is an inhibitor of cyclin-dependent kinase (CDK) 4 and 6 and causes tumor growth inhibition.
  • Adverse events include neutropenia, nausea, infections, fatigue, diarrhea, leukopenia, vomiting, alopecia, headache, constipation, rash, and cough.
  • Interactions: Avoid concomitant use of ribociclib with strong CYP3A inhibitors. Avoid concomitant use of ribociclib with strong CYP3A inducers. Avoid concomitant use of drugs known to prolong QT interval, such as anti-arrhythmic medicines.
  • Manufactured by: Novartis

SOURCE:

Kisqali S-005 ML3/SCAR (novartis.us)